Model-based assessment of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure.
The tetravalent dengue vaccine CYD-TDV (Dengvaxia) is the first licensed vaccine against dengue, but recent findings indicate an elevated risk of severe disease among vaccinees without prior dengue virus (DENV) exposure. The World Health Organization currently recommends CYD-TDV only for individuals...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-07-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | https://doi.org/10.1371/journal.pntd.0007482 |